NCT05049746

Brief Summary

This study collects information and identifies decision making needs for older adult women with stage I-III breast cancer considering neoadjuvant and adjuvant chemotherapy. Using this information, a decision support tool is then developed to provide patients and physicians with tailored information regarding the risks and benefits of chemotherapy and values clarification to support high-quality, shared decision. Subsequently, the decision support tool will be tested amongst older patients with early-stage breast cancer and health care providers navigating the decision process around chemotherapy, and further refined through an iterative process.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
95

participants targeted

Target at P50-P75 for not_applicable

Timeline
9mo left

Started Feb 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress93%
Feb 2016Feb 2027

Study Start

First participant enrolled

February 23, 2016

Completed
5.4 years until next milestone

First Submitted

Initial submission to the registry

August 2, 2021

Completed
2 months until next milestone

First Posted

Study publicly available on registry

September 20, 2021

Completed
5.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 2, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 2, 2027

Last Updated

May 1, 2026

Status Verified

April 1, 2026

Enrollment Period

11 years

First QC Date

August 2, 2021

Last Update Submit

April 27, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Decision making needs assessment questionnaire

    The mean score of the shared decision making questionnaire and its standard deviation along with the median and the range will be computed for both the patient and physician study population. Score Range-(0-4) 0-Not at all confident 4-very confident

    through study completion, an average of 1 year

Study Arms (2)

Intervention Arm

OTHER

Participants in the intervention arm only will then be asked to look at the decision tool that includes educational materials about the diagnosis and treatment of breast cancer. These could be written information, graphics, videos, animations, or questionnaires. This decision tool will personalize the decision to you specifically and support your decision-making process

Other: DiscussionOther: InterviewOther: Questionnaire Administration

Non-Intervention Arm

NO INTERVENTION

Participants undergo interviews and complete questionnaires over 1-2 hours. Patients and physicians also participate in a discussion and complete shared decision-making questionnaire over 15-30 minutes.

Interventions

Participate in discussion

Also known as: Discuss
Intervention Arm

Participate in interview

Intervention Arm

Complete questionnaire

Intervention Arm

Eligibility Criteria

Age65 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsOlder Adult (65+)

You may qualify if:

  • Women aged 65 years or older
  • Must write and speak English
  • Must have been diagnosed with Stage I-III breast cancer
  • Must have made decision to either receive or not receive neoadjuvant or adjuvant chemotherapy
  • Must be within 3 months of breast cancer neoadjuvant or adjuvant chemotherapy treatment decision
  • Self-reported no visual or auditory deficits
  • SUBAIM 2b: Women aged 65 years or older
  • SUBAIM 2b: Must write and speak English
  • SUBAIM 2b: Must have been diagnosed with stage I-III breast cancer
  • SUBAIM 2b: Must be a candidate for chemotherapy or targeted therapy (in the setting of HER2+ breast cancer)
  • SUBAIM 2b: Must be making a decision regarding chemotherapy
  • SUBAIM 2b: Self-reported no visual or auditory deficits
  • Physician for patient recruited to participate in study (physician criteria)

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

M D Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Related Links

MeSH Terms

Interventions

Interviews as Topic

Intervention Hierarchy (Ancestors)

Data CollectionEpidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Officials

  • Meghan Karuturi

    M.D. Anderson Cancer Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 2, 2021

First Posted

September 20, 2021

Study Start

February 23, 2016

Primary Completion (Estimated)

February 2, 2027

Study Completion (Estimated)

February 2, 2027

Last Updated

May 1, 2026

Record last verified: 2026-04

Locations